The China Securities Regulatory Commission has opened an investigation into Shenzhen Yahuilong Biotechnology Co., Ltd. after the company's Jan. 7, 2026 announcement that it had signed a strategic cooperation framework agreement was suspected of containing a misleading statement, and the regulator said it will handle the case in accordance with the law after completing a full investigation.